Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 22;32(167):220187.
doi: 10.1183/16000617.0187-2022. Print 2023 Mar 31.

Smoking cessation and vaccination

Maria Montes de Oca  1 , Maria Eugenia Laucho-Contreras  2
Affiliations

Smoking cessation and vaccination

Maria Montes de Oca et al. Eur Respir Rev. .

Abstract

A significant proportion of COPD patients (∼40%) continue smoking despite knowing that they have the disease. Smokers with COPD exhibit higher levels of nicotine dependence, and have lower self-efficacy and self-esteem, which affects their ability to quit smoking. Treatment should be adapted to the needs of individual patients with different levels of tobacco dependence. The combination of counselling plus pharmacotherapy is the most effective cessation treatment for COPD. In patients with severe COPD, varenicline and bupropion have been shown to have the highest abstinence rates compared with nicotine replacement therapy. There is a lack of evidence to support that smoking cessation reduction or harm reduction strategies have benefits in COPD patients. The long-term efficacy and safety of electronic cigarettes for smoking cessation need to be evaluated in high-risk populations; therefore, it is not possible to recommend their use for smoking cessation in COPD. Future studies with the new generation of nicotine vaccines are necessary to determine their effectiveness in smokers in general and in COPD patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Montes de Oca has received honoraria for lectures on COPD from AstraZeneca and GSK, outside the submitted work. M.E. Laucho-Contreras has received an honorarium for Medical Affairs Staff from GSK Colombia and owns GSK stock, all outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Prevalence of current-smoker COPD patients in different settings.
FIGURE 2
FIGURE 2
Assessment of smokers with COPD.
See this image and copyright information in PMC

Comment in

  • Nonpharmacological interventions in COPD.
    Janssens W, Verleden GM. Janssens W, et al. Eur Respir Rev. 2023 Mar 22;32(167):230028. doi: 10.1183/16000617.0028-2023. Print 2023 Mar 31. Eur Respir Rev. 2023. PMID: 36948503 Free PMC article.

References

    1. Cunalata-Paredes AV, Gea-Izquierdo E. COPD in the major nonsmoking adult: a systematic review and meta-analysis. Arch Environ Occup Health 2021; 76: 319–329. doi: 10.1080/19338244.2020.1828243 - DOI - PubMed
    1. Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018; 197: 1540–1551. doi: 10.1164/rccm.201710-2028PP - DOI - PMC - PubMed
    1. Bui DS, Lodge CJ, Burgess JA, et al. Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med 2018; 6: 535–544. doi: 10.1016/S2213-2600(18)30100-0 - DOI - PubMed
    1. Lange P, Celli B, Agusti A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373: 111–122. doi: 10.1056/NEJMoa1411532 - DOI - PubMed
    1. Martinez FD. Early-life origins of chronic obstructive pulmonary disease. N Engl J Med 2016; 375: 871–878. doi: 10.1056/NEJMra1603287 - DOI - PubMed

MeSH terms